FGFR3 and urothelial carcinoma: Other inhibitors of FGFR3 and F3T3 have also been tested in preclinical models and in trials in other tumor types, especially urothelial carcinoma and cholangiocarcinoma, for which therapeutics such as erdafitinib, rogaratinib, infigratinib, and the monoclonal antibody vofatamab have shown promise [12].